GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...

The British pharma said its shot didn’t meet the efficacy goals of a Phase 2 study. Elsewhere, Zealand reported more obesity ...

While they can heal naturally, preventing a fever blister from recurring should be a priority for anyone who has experienced ...

GSK has announced that Part II of the Phase I/II TH HSV REC-003 trial of its therapeutic herpes simplex virus (HSV) vaccine ...

GSK Plc’s experimental vaccine for herpes failed in an early-stage trial, halting an effort to bring the first shot for the ...

The words hit me like a punch in the stomach. I felt all the blood drain from my face and the air seep out of my lungs. Until ...

Caused mainly by herpes simplex virus type 2 (HSV-2), the disease is characterized by recurrent outbreaks in which the ...

GSK’s attempt to develop the first vaccine for herpes simplex virus (HSV) has ended in failure, leaving the race open for the ...

Without revealing specific details, GSK announced that it is terminating the development of its investigational herpes ...

British drugmaker GSK said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main ...

A study investigating GSK’s investigational herpes simplex virus (HSV) vaccine candidate failed to meet its primary efficacy endpoint.